Jun 24, 2011 by Brian Orelli, PhDCome On, Pfizer, Not Even a Little Hint?Remoxy is rejected, but why?
Jun 23, 2011 by Brian Orelli, PhDWill the FDA Approve Pfizer and Pain Therapeutics' Remoxy?Another FDA decision this week.
Jun 23, 2011 by Brian Orelli, PhDIn Addition, Our Drug Actually RocksPfizer and Bristol get good data on Eliquis.
Jun 22, 2011 by Brian Orelli, PhDIn-Licensing to the RescueAbbott's latest deal could help shore things up.
Jun 22, 2011 by Brian Orelli, PhDBuilding on Pfizer's BlockbusterNew data for an expanded indication for Lyrica.
Jun 21, 2011 by Brian Orelli, PhDData Look Good, Approval UnknownAccelerated approvals are like that.
Jun 20, 2011 by Brian Orelli, PhDSee Drug, Approve DrugAn approval of Regeneron's macular degeneration Eylea looks likely.
Jun 20, 2011 by Brian Orelli, PhDPfizer's Pain-Free FDA Approval. More to Come?Oxecta gains FDA approval. Remoxy is up next.
Jun 17, 2011 by Brian Orelli, PhDPick Your Poison: Lung Cancer or Heart AttackHow much will the FDA's new warning affect Pfizer's Chantix?
Jun 16, 2011 by Brian Orelli, PhDWill the FDA Approve Pfizer and Acura's Acurox?We'll know on Friday.
Jun 16, 2011 by Brian Orelli, PhDAre Two FDA Approvals in One Week a Positive Sign?Don't count on it.
Jun 15, 2011 by Brian Orelli, PhDInvestors Need a Peephole Into FDA OfficesCell Therapeutics is gung ho about its resubmission, but investors only get one side of the story.
Jun 15, 2011 by Brian Orelli, PhDWhich Path Will Spectrum Pharmaceuticals Take?It all depends on opportunities.
Jun 14, 2011 by Brian Orelli, PhD3 Ways to Play Biotech With OptionsThe road to riches doesn't have to be risky.
Jun 14, 2011 by Brian Orelli, PhDGoing for Seconds in the Hepatitis C SpaceVertex tries, tries, and tries again.
Jun 10, 2011 by Brian Orelli, PhDAbbott Picks Pumps Over PillsTreat Parkinson's disease, medical-device style.
Jun 10, 2011 by Brian Orelli, PhDGreat Data! Now Lets See More Than 12 PatientsMicromet's blinatumomab looks good in a phase 2 trial.
